We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.
- Authors
Brown, Alan S.; Gyllenberg, David; Malm, Heli; McKeague, Ian W.; Hinkka-Yli-Salomäki, Susanna; Artama, Miia; Gissler, Mika; Cheslack-Postava, Keely; Weissman, Myrna M.; Gingrich, Jay A.; Sourander, Andre
- Abstract
<bold>Importance: </bold>Speech/language, scholastic, and motor disorders are common in children. It is unknown whether exposure to selective serotonin reuptake inhibitors (SSRIs) during pregnancy influences susceptibility to these disorders.<bold>Objective: </bold>To examine whether SSRI exposure during pregnancy is associated with speech/language, scholastic, and motor disorders in offspring up to early adolescence.<bold>Design, Setting, and Participants: </bold>This prospective birth cohort study examined national population-based register data in Finland from 1996 to 2010. The sampling frame includes 845 345 pregnant women and their singleton offspring with data on maternal use of antidepressants and depression-related psychiatric disorders during pregnancy.<bold>Exposures: </bold>There were 3 groups of offspring: 15 596 were in the SSRI-exposed group, ie, had mothers diagnosed as having depression-related psychiatric disorders with a history of purchasing SSRIs during pregnancy; 9537 were in the unmedicated group, ie, had mothers diagnosed as having depression-related psychiatric disorders without a history of purchasing SSRIs during pregnancy; and 31 207 were in the unexposed group, ie, had mothers without a psychiatric diagnosis or a history of purchasing SSRIs.<bold>Main Outcomes and Measures: </bold>Cumulative incidence of speech/language, scholastic, or motor disorders (829, 187, and 285 instances, respectively) from birth to 14 years. All hypotheses tested were formulated before data collection.<bold>Results: </bold>Of the 56 340 infants included in the final cohort, 28 684 (50.9%) were male and 48 782 (86.6%) were 9 years or younger. The mean (SD) ages of children at diagnosis were 4.43 (1.67), 3.55 (2.67), and 7.73 (2.38) for speech/language, scholastic, and motor disorders, respectively. Offspring of mothers who purchased SSRIs at least twice during pregnancy had a significant 37% increased risk of speech/language disorders compared with offspring in the unmedicated group. The cumulative hazard of speech/language disorders was 0.0087 in the SSRI-exposed group vs 0.0061 in the unmedicated group (hazard ratio, 1.37; 95% CI, 1.11-1.70; P = .004). There was a significantly increased risk of these disorders in offspring in the SSRI-exposed and unmedicated groups compared with offspring in the unexposed group. For scholastic and motor disorders, there were no differences between offspring in the SSRI-exposed group and in the unmedicated group.<bold>Conclusions and Relevance: </bold>Exposure to SSRIs during pregnancy was associated with an increased risk of speech/language disorders. This finding may have implications for understanding associations between SSRIs and child development.
- Subjects
FINLAND; SEROTONIN uptake inhibitors; PREGNANCY complications; MOVEMENT disorders; SPEECH disorders; JUVENILE diseases; DIAGNOSIS of learning disabilities; SPEECH disorder diagnosis; ANTIDEPRESSANTS; MENTAL depression; LEARNING disabilities; LONGITUDINAL method; RELATIVE medical risk; WORD deafness; PROPORTIONAL hazards models; CASE-control method; PRENATAL exposure delayed effects; PSYCHOLOGY; DIAGNOSIS
- Publication
JAMA Psychiatry, 2016, Vol 73, Issue 11, p1163
- ISSN
2168-622X
- Publication type
journal article
- DOI
10.1001/jamapsychiatry.2016.2594